Gene therapy solution: The value of a CDMO as your end-to-end partner

With ongoing advances in science and technology, the cell and gene therapy pipeline has grown especially robust over the past few years. At present, Clinical shows more than 4,500 active gene therapy trials globally. In the United States, McKinsey experts expect to see 10 to 20 cell and gene therapy approvals per year over the next five years. 

This article discusses the important factors to consider when selecting an outsourcing partner for your advanced therapies. 

Download Article


Editorial: Good Manufacturing Practices: Challenges with Compliance

Dino Muzzin, Senior Vice President, Manufacturing Operations at Emergent, recently contributed to an article in BioPharm...


Focus on Fill and Finish

Kelly Christiansen, vice president & general manager of Emergent CDMO's Rockville drug product manufacturing facility recently...


BioPharm Intl Regulatory Sourcebook: GMPs Guide COVID-19 Vaccine Manufacturing

Excerpt taken from BioPharm International October 2020 Regulatory Sourcebook article titled: GMPs Guide COVID-19 Vaccine...